[1] 杨冰,陈小敏,毛捷,等. 原发性硬化性胆管炎临床试验的设计思路[J]. 肝脏,2019,24(4):350-354.DOI:10.3969/j.issn.1008-1704.2019.04.003.
[2] 尧颖,杨晋辉. 原发性硬化性胆管炎的治疗[J]. 胃肠病学,2007,12(6):380-382.DOI:10.3969/j.issn.1008-7125. 2007.06.017.
[3] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J].Control Clin Trials,1996,17(1):1-12.DOI:10.1016/0197-2456(95)00134-4.
[4] Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis[J].Am J Gastroenterol,2001,96(5):1558-1562.DOI:10.1111/j.1572-0241.2001. 03777.x.
[5] Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis[J].Gastroenterology,2001,121(4):900-907.DOI:10.1053/gast.2001.27965.
[6] Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study[J].Gastroenterology,2005,129(5):1464-1472.DOI:10.1053/j.gastro.2005.08.017.
[7] Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period[J].J Hepatol,1994,20(1):57-64.DOI:10.1016/s0168-8278(05)80467-2.
[8] Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group[J].N Engl J Med,1997,336(10):691-695.DOI:10.1056/NEJM199703063361003.
[9] 徐玉萍.原发性硬化性胆管炎临床治疗护理分析[J].大家健康(学术版),2013,7(19):40.
[10] 韩英,朱疆依. «原发性硬化性胆管炎诊断和治疗专家共识(2015)»推荐意见解读[J]. 临床肝胆病杂志,2016,32(3):420-422.DOI:10.3969/j.issn.1001-5256.2016.03.003.
[11] 彭焕彦,康富标,王燕,等. 原发性硬化性胆管炎的诊疗进展[J]. 解放军医学杂志,2016,41(11):965-969.DOI:10.11855/j.issn.0577-7402.2016.11.15.
[12] Björnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis[J].Gut,2002,51(5):731-735.DOI:10.1136/gut.51.5.731.
[13] Stone JH, Brito-Zerón P, Bosch X, et al. Diagnostic approach to the complexity of IgG4-related disease[J].Mayo Clin Proc,2015,90(7):927-939.DOI:10.1016/j.mayocp.2015.03.020.
[14] 俞力军,黄伟平. 熊去氧胆酸治疗原发性硬化性胆管炎的meta分析[J]. 实用医学杂志,2010,26(6):992-994.DOI:10.3969/j.issn.1006-5725.2010.06.050.
[15] 刘强. 熊去氧胆酸对原发性硬化性胆管炎疗效的Meta分析[J]. 世界最新医学信息文摘,2018,18(50):3-4.DOI:10.19613/j.cnki.1671-3141.2018.50.002.
|